Quantcast
Last updated on April 23, 2014 at 10:57 EDT

Latest Valeant Pharmaceuticals Stories

2013-04-04 08:28:37

MONTREAL, April 4, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today responded to a generic approval for Zovirax® ointment. "Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment," stated J. Michael Pearson. "While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an...

2013-04-03 08:27:50

MONTREAL, April 3, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Valeant and Obagi Medical Products, Inc. (NASDAQ: OMPI) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash. The offer documents will be amended to reflect the new offer price of $24.00 per share. The expiration date...

2013-03-29 20:20:41

MONTREAL, March 29, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary Valeant Pharmaceuticals International (the "Company") intends to commence an offer to exchange (the "Exchange Offer") any and all of its outstanding $500 million aggregate principal amount of 6.375% Senior Notes due 2020 (the "Existing Notes") for up to an additional $500 million aggregate principal amount of its 6.375% Senior Notes due...

2013-03-27 12:26:16

WILMINGTON, Del., March 27, 2013 /PRNewswire/ -- Rigrodsky & Long, P.A.: Do you own shares of Obagi Medical Products, Inc. (NASDAQ GS: OMPI)? Did you purchase any of your shares prior to March 20, 2013? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Obagi Medical Products, Inc. ("Obagi" or the "Company") (NASDAQ...

2013-03-20 08:26:42

MONTREAL, March 20, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement. The transaction is expected to close in the first...

2013-03-01 16:25:08

Brand donates $15,000 to fund grant program for skin of color dermatological research MIAMI BEACH, Fla., March 1, 2013 /PRNewswire/ -- AMBI® Skincare is pleased to announce the annual AMBI Research Award with The Skin of Color Society, a grant of $15,000 to promote dermatology research within the field of skin of color. By providing essential funding to this program, AMBI and the Skin of Color Society are helping to shape the future of tomorrow's clinical leaders in...

2013-02-25 08:30:25

Brings Extensive Leadership And Operations Experience in Healthcare Industry MALVERN, Pa., Feb. 25, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Rajiv De Silva, a pharmaceutical executive who had been President of Valeant Pharmaceuticals and a senior executive at Novartis, has been named Endo's President and Chief Executive Officer, effective March 18. Mr. De Silva, who will also join the Endo Board of Directors, succeeds David Holveck who is...

2013-02-21 08:31:07

WOODCLIFF LAKE, NJ. and MONTREAL, Quebec, Feb. 21, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE: VRX)(TSX: VRX) announced today that Valeant has acquired U.S. rights for Targretin(®) (bexarotene) capsules and Targretin(®) (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones. (Photo:...

2013-02-01 08:26:13

MONTREAL, Feb. 1, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of Natur Produkt International, JSC, a specialty pharmaceutical company in Russia, for approximately $163 million, plus adjustments for net debt and working capital. Natur Produkt has a significant presence in the over-the-counter (OTC) segment in several categories marketed under the umbrella brand, Natur Produkt. Key brands include...

2013-01-31 08:30:06

MONTREAL, Jan. 31, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 28, 2013 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2012 fourth quarter. The dial-in number to participate on this call is (877) 295-5743, confirmation code 94189232. International callers should dial (973) 200-3961, confirmation code...